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Background: Uremic pruritus (UP) is a significant complication in ESRD patients and substantially impairs their
quality of life. UP is considered to be a skin manifestation of chronic inflammation. Because sericin can suppress
the release of pro-inflammatory cytokines, the purpose of this study was to investigate the short-term safety
and efficacy of sericin cream for treating UP in hemodialysis patients.
Methods: This study used a double-blind design to investigate the effects of random topical administration of
sericin cream and cream base (placebo) on either the right or left extremities of hemodialysis patients for 6 weeks.
Skin hydration, irritation and pigmentation were evaluated every 2 weeks using Skin Diagnostic SD27. The visual
analog scale for itching was also evaluated every 2 weeks, and the Kidney Disease Quality of Life Short Form was
performed on the day of each patient’s enrollment and after 6 weeks of treatment.
Results: Fifty dialysis patients were enrolled, 47 of which completed the study. The hydration of the skin of the
patients’ extremities increased significantly after administration of sericin cream; significant differences were found
between sericin treatment and control after 6 weeks of treatment (p= 0.041 for arms and p= 0.022 for legs,
respectively). Moreover, a significant difference was also found in skin irritation between the two treatments
(p= 0.013 for arms and p= 0.027 for legs, respectively). At the end of the study, the skin pigmentation level was
significantly reduced on both the arms (p= 0.032) and legs (p= 0.021) of the sericin-treated side compared with
the side treated with cream base. The mean itching score decreased significantly from moderate to severe at the
time of enrollment to mild pruritus after 6 weeks of treatment (p= 0.002). A better quality of life was found in
all domains tested although statistically significant differences before and after treatment was found only in the
patients’ pain scores, the effect of kidney disease on daily life, sleep quality and symptoms or problems related
to kidney disease.
Conclusions: We conclude that sericin cream has a high potential for reducing UP in hemodialysis patients.
The trial registration number of this study is ISRCTN16019033; its public title is “sericin cream reduces pruritus
in hemodialysis patients”.
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Table 1 Amino acid composition of sericin
Amino acid Amount (%)
Serine (Ser) 33.63
Aspartic acid (Asp) 15.64
Glycine (Gly) 15.03
Threonine (Thr) 8.16













These mean values were obtained by triplicate analysis.
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Itching associated with end-stage renal disease (ESRD)
or uremic pruritus (UP) affects between 20 and 50% of
renal failure patients [1-3] who have no primary skin
disease or systemic or psychological dysfunction that
might cause pruritus. In addition, approximately 80% of
patients undergoing hemodialysis were found to be
affected by UP [4-6]. Unfortunately, dialysis has only a
slight impact on pruritus [7].
Pruritus is an unpleasant symptom that negatively
impacts a patient’s quality of life. The impact of moder-
ate/severe uremic pruritus on the mortality of patients
with ESRD seems to be associated with sleep disturbance
rather than with uremic pruritus per se [8,9]. Moreover,
in the recent Dialysis Outcomes and Practice Patterns
Study II (DOPPS II) trial, pruritus was associated with
depression, sleep disturbance and increased mortality
risk [8,10]. The pathophysiology of UP is still unclear;
many hypotheses have been proposed to explain its oc-
currence, including xerosis and hypohidrosis (a condi-
tion in which the skin is usually atrophic and dry), the
presence of pruritogenic cytokines (histamine, kallikrein,
interleukin [IL]-2, acetylcholine and other substances
that are released by histamine-mediated mast cell stimu-
lation and may lower the UP threshold), secondary
hyperparathyroidism, immune-inflammatory reactions in
which sericin cream is thought to play a central role
in producing an anti-inflammatory effect, the uremic
neuropathy hypothesis and the opioid hypothesis
(k-opioid receptor understimulation and overexpression
of μ-opioid receptors) [7,8].
Sericin, a biopolymer with a high molecular weight, is a
water-soluble protein that is obtained from the silkworm
(Bombyx mori) [11]. Sericin is characterized by the pres-
ence of 32% serine, which is the main amino acid of the
natural moisture factor (NMF) in human skin; therefore,
sericin has excellent moisturizing properties that may
be helpful for treating hypohidrosis. Sericin also shows
many biological activities and has been widely studied for
potential use in medicines and biomaterials [12-16]. In
2009, Aramwit et al. showed that sericin significantly
decreased the levels of the pro-inflammatory cytokines
tumor necrosis factor-α (TNF-α) and interleukin-1β
(IL-1β) in sericin-treated wounds in rats 7 days after an
injury compared with the levels found in normal saline-
soaked wounds and cream base-treated wounds [17]. As
previously mentioned, the immune-inflammatory hypoth-
esis considers UP a dermatologic manifestation of chronic
inflammation and treats the condition as a possible result
of derangements in the immune system that are based on
a pro-inflammatory pattern. Based on this reasoning, seri-
cin may help to relieve UP.
At present, there is no widely accepted treatment
for UP. Topical products, such as moisturizers andemollients, are typically used to alleviate symptoms.
Because sericin can suppress the release of pro-
inflammatory cytokines, the present study was designed
to investigate the short-term safety and efficacy of seri-
cin cream for treating UP in ESRD patients. The quality
of life of ESRD patients after using sericin cream was
also evaluated.
Results
Molecular weight and amino acid composition of sericin
Sodium dodecyl sulfate polyacrylamide gel electrophor-
esis (SDS-PAGE) of sericin prepared by the high-
temperature and high-pressure degumming technique
showed continuous bands with molecular weights ran-
ging from 50–150 kDa. The highest-intensity band had
an apparent molecular weight of approximately 100 kDa.
The amino acid composition of sericin extracted with
this method is given in Table 1.
Study population
Fifty hemodialysis patients with ESRD were enrolled in
this study; however, only 47 subjects completed the
treatment (3 patients were withdrawn due to relocation).
Thirty of the 47 subjects were female (63.83%), and 17
were male (36.17%); the mean age was 49.6 ± 11.2 years.
The average duration of dialysis was 24.6 ± 3.1 months.
Table 2 shows the characteristics and biochemical para-
meters of the study population. Most of the biochemical
parameters, such as calcium (9.87 ± 1.32 mg/dL), phos-
phorus (4.35 ± 1.02 mg/dL), albumin (3.96 ± 0.62 g/dL),
Table 2 Baseline characteristics of subjects (N=47)
Characteristics
Gender (M:F) 17:30
Age (years) 49.6 ± 11.2
Dialysis duration (months) 24.6 ± 3.1
Hematocrit (%) 30.12 ± 3.55
BUN (mg/dL) 57.89 ± 12.65
Creatinine (mg/dL) 10.98 ± 2.25
Calcium (mg/dL) 9.87 ± 1.32
Phosphorus (mg/dL) 4.35 ± 1.02
Albumin (g/dL) 3.96 ± 0.62
ALT (IU/L) 14.23 ± 5.98
AST (IU/L) 15.32 ± 5.12
Alkaline phosphatase (IU/L) 96.58 ± 40.32
Total bilirubin (mg/dL) 0.32 ± 0.11
Itching (scale 1–10) 7.05 ± 2.17
Skin parameters Sericin cream treatment Cream base treatment p-value
Skin hydration
Arm 28.67 ± 7.11 27.55 ± 7.84 0.819
(13.90-44.90) (13.36-44.34)
Leg 25.10 ± 7.67 23.29 ± 7.37 0.982
(13.98-49.70) (7.74-38.88)
Skin irritation
Arm 409.34 ± 232.09 318.50 ± 484.26 0.892
(177.60-1,441.00) (217.00-2,558.40)
Leg 364.74 ± 120.20 308.22 ± 116.14 0.857
(177.00-685.40) (158.80-818.20)
Skin pigmentation
Arm 373.56 ± 142.32 360.35 ± 249.29 0.834
(155.60-729.80) (145.80-1,400.00)
Leg 435.94 ± 178.06 402.25 ± 154.53 0.901
(199.00-1,182.80) (196.00-811.00)
BUN=blood urea nitrogen, ALT = alanine transaminase, AST = aspartate aminotransferase.
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(alanine transaminase (ALT) 14.23 ± 5.98 IU/L, aspartate
aminotransferase (AST) 15.32 ± 5.12 IU/L and alkaline
phosphatase 96.58 ± 40.32 IU/L) levels, were within the
normal range. The baseline characteristics of each par-
ameter, including skin hydration, skin irritation and skin
pigmentation on the right and left extremities, showed
no significant differences (p= 0.819 and 0.982 for skin
hydration on arms and legs, p= 0.892 and 0.857 for skin
irritation on arms and legs, p= 0.834 and 0.901 for
skin pigmentation on arms and legs, respectively). The
average itching score of the subjects using the visual
analogue scale (VAS) at baseline was 7.05, which was
considered moderate to severe (VAS < 4.0 is considered
to reflect mild pruritus, while VAS 4.0 - 6.9 indicatesmoderate pruritus, and VAS > 7.0 is considered to indi-
cate severe pruritus [10]). At baseline, both the arms and
legs of the subjects showed some degree of skin irrita-
tion. None of the subjects reported any allergy or der-
matological symptoms caused by the sericin or the
cream base.
The level of skin hydration in the patients’ extremities
increased after treatment with either sericin or cream
base. The same patients received sericin and placebo
(cream base) treatment and that application of each
compound were confined to one side of the body. On
the sericin-treated side of the body, the skin hydration of
the arms was 28.67 ± 7.11 at baseline, and it increased
to 33.62 ± 6.93 after treatment for 6 weeks (p= 0.047),
while the skin hydration of the legs, which was 25.10 ±
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of treatment (p= 0.025). On the cream-base-treated side
of the body, the skin hydration of the arms was 27.55 ±
7.84 at baseline, and it increased to 29.40 ± 4.92 after
treatment for 6 weeks (p= 0.593); the skin hydration of
the legs, which was 23.29 ± 7.37 at baseline, changed to
26.02 ± 6.47 after 6 weeks of treatment (p= 0.276). The
skin hydration changes were significantly higher on the
side that received the sericin cream than on the side that
received the cream base, and a significant difference
between the sericin cream and cream base treatments
was found in the level of skin hydration in both the arms
and legs during the sixth week of treatment (p= 0.041
for arms and p= 0.022 for legs, respectively). Table 3
shows the skin parameters for hydration (measured by
the Corneometer) and for irritation and pigmentation
(measured by the Mexameter) of the subjects’ extrem-
ities at weeks 2, 4 and 6 after treatment. Figures 1 and 2
illustrate the percent changes in the parameters of the
skin that received the sericin cream or the cream base
during weeks 2–6 compared to the baseline. Six weeks
after treatment, the average level of skin hydration on
the side of the body that received the sericin cream was
significantly increased compared to the baseline
(p= 0.047 for arms and p= 0.025 for legs), while the side
that received the cream base showed no significant dif-
ference (p= 0.593 for arms and p= 0.276 for legs) in skin
hydration. The arms of the patients who were treated
with the sericin cream showed significant differences in
the level of skin hydration four weeks after the treatment
compared to baseline (p= 0.022).
Skin irritation was measured based on the redness of
the skin; both the sericin cream and the cream base
reduced the level of skin irritation throughout the study
period. As shown in Table 3, the arms and legs that were
treated with sericin cream showed statistically signifi-
cantly reduced irritation or redness from the second
week after treatment until the end of the studyTable 3 Skin parameters of hydration, irritation and pigment
Parameters Baseline 2nd Week
SS cream Cream base SS cream Cream ba
Hydration
Arm 28.67±7.11 27.55±7.84 29.59±6.07 28.00±5.7
Leg 25.10±7.67 23.29±7.37 25.72±5.74 24.16±5.9
Irritation
Arm 409.34±232.09 318.50±484.26 283.85±77.33* 302.17±74
Leg 364.74±120.20 308.22±116.14 295.59±75.21* 283.82±75
Pigmentation
Arm 373.56±142.32 360.35±249.29 308.09±108.37* 342.73±13
Leg 435.94±178.06 402.25±154.53 374.51±131.43* 386.38±14
* indicates a significant difference compared with the same treatment at baseline (
SS = silk sericin.compared to the baseline (p= 0.031 for arms and
p= 0.040 for legs). The degree of redness of the legs of
the patients who were treated with the cream base dur-
ing weeks 4 (p= 0.048) and week 6 (p= 0.036) was also
significantly reduced compared to the baseline. In addi-
tion, a significant difference between treatment with
sericin cream and cream base was found in the level of
skin irritation of both arms (p=0.013) and legs (p=0.027)
after 6 weeks of treatment.
The use of sericin cream significantly reduced the
darkness of the skin on both the arms and legs of the
patients, as shown in Table 3. In addition, in the sixth
week of treatment, there was a significant difference in
the level of skin pigmentation in the arms and legs trea-
ted with the sericin cream compared to those treated
with the cream base (Figures 1 and 2, p= 0.032 for arms
and p= 0.021 for legs, respectively). The cream base
showed no statistically significant effect on the level of
skin pigmentation, and no significant difference com-
pared to baseline was found in the skin pigmentation of
the patients’ arms and legs after use of the cream base
for 6 weeks (p= 0.082 for arms and p= 0.067 for legs,
respectively).
The mean VAS scores for itching at baseline and after
2, 4 and 6 weeks of treatment are shown in Figure 3; the
scores shown are based on the overall symptoms without
differentiating between the sericin cream and cream base
treatments. The mean pruritus score gradually decreased
from the beginning of the study and with increasing
weeks of treatment. The mean pruritus score at baseline
was 7.05 ± 2.17 (range 1–10, median 8), which is indi-
cates moderate to severe pruritus [10,18]; the mean
score decreased to 2.23 ± 1.73 (range 0–6, median 2),
indicating mild pruritus [10,18], after 6 weeks of treat-
ment (p= 0.008).
Table 4 shows the mean score assigned to each
domain of the Kidney Disease Quality of Life Short
Form (KDQOL-SF) by the hemodialysis patients on theation on the subjects’ extremities after treatment
4th Week 6th Week
se SS cream Cream base SS cream Cream base
3 32.41±7.10* 29.36±6.01 33.62±6.93* 29.40±4.92
5 27.24±6.23 26.43±5.90 29.05±7.74* 26.02±6.47
.87 276.53±66.67* 286.29±77.26 260.71±69.30* 291.24±82.68
.04 267.93±78.03* 255.42±74.78* 261.54±79.77* 256.46±69.06*
0.47 302.62±111.02* 349.71±132.26 285.42±116.99* 338.88±115.54


















































Figure 1 Changes in skin parameters of hydration, irritation and pigmentation on the arms. Detailed legend: The changes in the skin
parameters of hydration (measured by Corneometer), irritation and pigmentation (measured by Mexameter) on patients’ arms treated with sericin
cream or with cream base at weeks 2, 4 and 6 of treatment compared to baseline (* indicates significant differences compared to baseline;
# indicates significant differences between treatments) (p< 0.05).
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above, the quality-of-life score was based on the patients’
overall symptoms without differentiating between the
sericin cream and cream base treatments. On the enroll-
ment day, the mean scores ranged from 43.05 for
general health to 83.84 for the domain related to dialysis










































Figure 2 Changes in skin parameters of hydration and irritation and p
parameters of hydration (measured by Corneometer), irritation and pigmen
cream or cream base at weeks 2, 4 and 6 of treatment compared to baseli
significant differences between treatment) (p< 0.05).mean scores ranged from 44.21 for kidney disease bur-
den to 87.50 for encouragement by the dialysis staff. We
found a better quality of life in all the measured
domains, including sleep and mood/emotional distress,
after the treatment period. When the mean score on
the enrollment day was compared with the mean score










igmentation on the legs. Detailed legend: The changes in the skin
tation (measured by Mexameter) on patients’ legs treated with sericin
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Figure 3 The mean VAS score for itching. Detailed legend: The mean VAS score for itching at baseline and after 2, 4 and 6 weeks of treatment
(* indicates significant difference, p< 0.05).
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(p= 0.001), the symptoms/problems list in kidney disease
(p= 0.000), the effect of kidney disease on daily life
(p= 0.008) and sleep, the most relevant parameter for
itching (p= 0.014). The overall score increased from
60.00 at the time of enrollment to 61.95 after 6 weeks of
treatment, although this difference was not statistically
significant (p= 0.091).
Discussion
This study has shown that the use of sericin cream can
reduce UP in hemodialysis patients according to their
VAS scores. Sericin cream can also significantly increase
skin hydration and reduce skin irritation and skin pig-
mentation in patients. The molecular weight analysis of
the sericin used in this study gave results that agree with
those reported by Sprague, who indicated that sericin is
a mixture of at least 15 different polypeptide chains ran-
ging in size from 20–220 kDa [19]. Similar to the earlier
report by Kato et al., serine was the most abundant
amino acid found in sericin [20].
Although antihistamines, anti-allergic agents and top-
ical corticosteroids are commonly used to treat UP in
ESRD patients, their effectiveness is sometimes limited
[2,8,21,22]. Alternative and effective treatments for intract-
able pruritus that generate low levels of adverse reactions,
particularly in sensitive patients such as the ESRD group,
must therefore be developed. This clinical study is the first
to suggest that a sericin cream is beneficial for treating
pruritus in hemodialysis patients. The benefits of this
treatment apparently result from increases in skin hydra-
tion and suppression of pro-inflammatory cytokines, as
shown in our earlier study [17,23], thereby resulting in less
skin irritation without any allergic reactions.Pruritus associated with chronic kidney disease has
been shown to be associated with elevated levels of C-
reactive protein and other inflammatory cytokines. This
evidence suggests that there is an inflammatory compo-
nent in this form of pruritus [24]. Some authors consider
UP to be a skin manifestation of chronic inflammation
[25]. Recently, the “persistent microinflammation” the-
ory, in which it is suggested that inflammation may be
related to the genesis of UP, was proposed [26]. The skin
of ESRD patients with UP contains an increased number
of mast cells, and these cells can release various sub-
stances such as histamine, interleukins (IL) and tumor
necrosis factor (TNF) [27-30].
Pruritic skin can appear normal except for dryness;
because the severity of pruritus is closely correlated
with skin dryness [31], xerosis treatment normally begins
with a topical agent such as a gentle moisturizing cream.
Because sericin is well known for its moisturizing
effect and its ability to reduce the generation of pro-
inflammatory cytokines by fibroblasts, this study assessed
the usefulness of sericin cream in treating UP. Evaluating
the degree of pruritus was difficult because it is a sub-
jective symptom; therefore, functional measurements of
skin conditions known to be associated with pruritus,
such as skin hydration and skin irritation, were consid-
ered to be objective indices. We found that both sericin
cream and the cream base used to prepare the sericin
cream increased the moisture content of the stratum
corneum; however, the level of hydration was signifi-
cantly higher in the skin treated with sericin cream. The
side of the body treated with sericin cream had signifi-
cantly lower levels of post-treatment dryness compared
to pretreatment dryness and lower total dermatological
severity scores in parameters such as skin pigmentation.
Table 4 Mean scores for each domain of the KDQOL-SF in
hemodialysis patients on the enrollment day and after





Physical component score (PCS)
Physical functioning 73.90 ± 18.99 77.93 ± 18.57
Role limitations-physical 50.00 ± 42.20 51.83 ± 44.16
Pain 48.29 ± 16.96 74.27 ± 17.36*
General health 43.05 ± 24.08 47.32 ± 22.17
Mental component score (MCS)
Energy/fatigue 50.73 ± 18.93 56.59 ± 17.62
Social function 69.82 ± 20.53 78.35 ± 22.54
Role limitations-emotional 56.10 ± 42.45 61.79 ± 41.87
Emotional well-being 61.17 ± 15.60 64.98 ± 16.51
Kidney disease component score (KDCS)
Symptoms/problems list 64.33 ± 9.98 78.51 ± 10.44*
Effect of kidney disease on daily life 59.91 ± 20.46 68.22 ± 16.33*
Burden of kidney disease 43.45 ± 29.38 44.21 ± 25.29
Cognitive function 65.53 ± 18.25 69.27 ± 19.43
Work status 60.98 ± 41.10 68.29 ± 39.93
Sexual function 71.74 ± 33.12 75.00 ± 23.62
Quality of social interaction 70.08 ± 18.80 76.91 ± 16.06
Sleep 43.41 ± 22.08 52.74 ± 18.22*
Social support 70.33 ± 22.52 76.02 ± 25.01
Dialysis staff encouragement 83.84 ± 13.76 87.50 ± 12.18
Patient satisfaction 70.73 ± 20.34 78.05 ± 17.65
Overall score 60.00 ± 21.68 61.95 ± 19.90
* Indicates significant differences compared to baseline, p< 0.05.
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inflammation and oxidative stress, as reflected in studies
of plasma biochemistry, including the levels of the
cytokines IL and TNF-α [32-34], classic markers of
inflammatory processes that are strongly affected by
pathological conditions [35]. These cytokines are upre-
gulated in the plasma of ESRD patients [32,36]. The skin
inflammation associated with the release of IL and TNF-
α is further complicated by the inflammatory lesions that
occur secondary to scratching [37]. Our results indicate
that improvement in skin hydration and suppression of
the release of pro-inflammatory cytokines in skin might
be the mechanism by which sericin improves UP. Skin
irritation, which can be caused by either skin inflamma-
tion or by scratching, was substantially reduced in the
sericin group compared with the cream base group after
6 weeks of treatment. This result confirmed that sericin
reduces skin irritation in patients with UP and suggested
that it might be due to suppression of the inflammatorycytokines in skin. Similar results have been obtained in
animal studies [23].
Secondary skin lesions that can result from the itch-
scratch cycle include excoriations, hyperpigmentation,
lichenification, prurigo nodules and scars [38]. Chronic
renal failure is usually accompanied by a variety of cuta-
neous manifestations; dermal manifestations, including
hyperpigmentation, have also been reported, and these
can exact a considerable toll on the quality of life [39-41].
Although skin pigmentation is not related to specific clin-
ical symptoms, it has an important effect on patient satis-
faction. Sericin has been reported to have activity against
tyrosinase [15], an enzyme related to melanin production;
as this study shows, treatment with sericin results in sig-
nificant reduction in the skin color of patients.
The pruritus/mortality relationship may be strongly
attributed to sleep disturbances, as previously mentioned
in the DOPPS [8,9,42]. Many previous studies have
found a strong association between inflammation, as
measured by C-reactive protein or inflammatory cyto-
kines, and sleep disturbances in dialysis patients [43-45].
The significant effects of pruritus on sleep, mood and
social functioning require further investigation with the
goal of improving the available treatments for this ser-
ious ESRD complication. We found that reduction in
itching intensity from moderate to severe pruritus at the
time of enrollment to mild pruritus after 6 weeks of
treatment was associated with a better quality of life in
all of the measured domains, including the mental, phys-
ical and kidney disease components. The KDQOL-SF
score in the ESRD patients indicated improvements in
several domains regarding the patients’ quality of life,
particularly pain and sleep, which are relevant to itching.
A better quality of sleep may reflect some degree of
relief from itching achieved through the treatments.
This study has certain limitations. First, the study
design was an in-subject controlled study; it cannot be
determined whether the improvements in the itching
evaluation and the quality of life were from the sample
(sericin cream) or the placebo (cream base). Moreover,
due to the in-subject controlled design, the biochemical
parameters could not be evaluated at the end of the
study. Second, the study included a small number of
patients, and these were followed for a relatively short
time. A long-term study with a larger sample size is
necessary. In addition to studies of hemodialysis patients,
similar studies of other ESRD patients, such as peritoneal
dialysis and kidney transplant patients, are also necessary
to confirm the findings presented here.
Conclusions
Our study shows that sericin reduces pruritus in patients
with UP. The use of sericin cream significantly increased
the level of skin hydration after 6 weeks of treatment
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The use of sericin cream also significantly reduced the
level of skin irritation and pigmentation after 6 weeks of
treatment compared to baseline, while use of the cream
base reduced skin pigmentation slightly but not signifi-
cantly. The results of this study suggest that sericin
cream may be a good choice for treating pruritus in
hemodialysis patients.
Methods
Preparation of silk sericin cream
Because commercial sericin cream is unavailable, the
sericin cream used in this study was prepared from raw
materials. Bombyx mori cocoons were purchased from
Chul Thai Silk Co., Ltd. (Petchaboon province, Thailand).
The cocoons were extracted with purified water (1 g of
dry silk cocoon: 30 mL of water) using a high
temperature and pressure degumming technique in an
autoclave (SS-320, Tomy Seiko Co., Ltd., Tokyo, Japan)
at 121°C and 15 psi for 60 min. This technique has been
shown to be safe for the preparation of material used on
keratinocyte and fibroblast cells and can activate high
collagen production related to wound healing [46]. After
filtration through a membrane (Whatman filter paper
No. 1, Whatman PLC, Kent, United Kingdom) to remove
fibroin, sericin powder was obtained by freezing and
lyophilizing the sericin solution with a Heto LL3000
lyophilizer (Allrod, Denmark). Petroleum jelly, mineral oil,
lanolin, glycerin, bisabolol, triethanolamine stearate, propyl-
paraben and methylparaben were used to formulate a
cream base. For an 8% sericin cream, a concentration that
has been shown to be safe and effective in the treatment of
second-degree burn wounds, the sericin powder was dis-
solved in warm water and then mixed with the other ingre-
dients during the cream-forming process.
Molecular weight determination of sericin
To determine the molecular weight of sericin, SDS-
PAGE was performed as previously described, with
some modifications [47]. Briefly, samples were prepared
for SDS-PAGE by adding an equal volume of sample
buffer (0.25 M Tris–HCl, pH 7.0 containing 4% SDS,
10% sucrose, 10% 2-mercaptoethanol and 0.025% bro-
mophenol blue) to each protein solution. Each sample
was then incubated at 98°C for 2–3 min and loaded onto
a 5%-20% gradient gel (Atto Corporation, Tokyo, Japan).
Electrophoresis was performed in 125 mM Tris base
with 0.96 M glycine and 0.5% SDS, and the polypeptide
bands were detected using silver staining.
Amino acid analysis of sericin
The amino acid composition of sericin was determined
using an amino acid analyzer (Hitachi L-8500A, Tokyo,
Japan). Samples for analysis were hydrolyzed in 4 Mmethanesulfonic acid containing 0.2% 3-(2-aminoethyl)
indole (Wako Pure Chemical Industries, Ltd., Tokyo, Japan)
at 100°C for 24 h under vacuum. The experiments were
performed in triplicate.
Study design
Skin hydration may be related to pruritus, and this par-
ameter is sensitive to relative humidity, personal activ-
ities and diet. Therefore, an in-subject control using a
split-body biometrological assessment (each patient
received both treatments but on different sides of the
body) was used to evaluate the safety and efficacy of the
sericin cream for the treatment of UP in hemodialysis
patients. Moreover, the distribution of pruritus between
the patients was highly variable whereas the manifest-
ation of mirror symmetry was an attribute they all
shared [48]. An in-subject, randomized, double-blind,
placebo-controlled experimental study was designed to
investigate the effects of the sericin cream versus the
cream base (placebo) in reducing the symptoms of UP
(itching, dryness and redness) and skin pigmentation in
stable maintenance hemodialysis patients. Each of the
parameters, including skin hydration, skin irritation, skin
pigmentation and itching score, was evaluated at base-
line and at 2, 4 and 6 weeks after treatment intervention.
The sericin cream and the cream base were identical in
texture and scent. All of the products were packaged
in containers that were label-free except for the treat-
ment code number, and the packages were identical in
shape, size and color; therefore, the treatment assign-
ment remained unknown to the participants, the study
investigators and the medical personnel. The subjects
were recruited from December 2010 to February 2011,
and the study was conducted between March 2011 and
December 2011 at the Division of Nephrology,
Phramongkutklao Hospital and at Priest Hospital,
Thailand. Signed informed consent was obtained from all
subjects after a thorough discussion of the protocol, its ra-
tionale and the potential risks. This study was approved by
the Ethics Committee of the Institute Review Board at
Phramongkutklao Hospital, Thailand and ended after the
last participant completed the intervention.
Study population
Inclusion criteria
All ESRD patients at Phramongkutklao and Priest
Hospitals over 18 years of age who had received hemo-
dialysis for at least 3 months were screened for this
study. Having mild to severe pruritus as measured by
the VAS during the previous 6 weeks was also an inclu-
sion criterion. The patients were required to refrain
from using any antipruritic treatment (oral or topical)
for a period of not less than 2 weeks prior to the start
of the study. Patients of both genders, regardless of
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Any medication that had an antipruritic effect was dis-
continued 2 weeks before the study. No changes in the
patients’ prescription medications were required during
this study with the exception of a concomitant antiprur-
itic treatment.Exclusion criteria
Pruritus caused by other skin diseases or medication was
excluded by careful clinical assessment. Patients with a
history of silk protein allergy, who were allergic to any
compounds in the formula, or who had biliary atresia,
liver problems, cancer, metabolic disorders or other dis-
eases related to systemic pruritus were also excluded.
Patients who had skin problems or rashes on their ex-
tremities (arms or legs) were also excluded from this
study. Participants left the project when they could not
comply with the treatment, when they were unwilling to
continue with the study, or when the physician opined
that other treatments were needed to relieve the symp-
toms. After reviewing patient profiles and explaining the
protocol, 27 patients were excluded due to liver pro-
blems (N= 4), cancer (N= 3), metabolic disorder (N = 7),
rashes on their extremities (N = 6) and refusal to partici-
pate in the study (N= 7). The remaining patients
(N= 50) were enrolled in the study.Study treatment
In 2004, Okada and Matsumoto [49] evaluated the effect
of an emollient containing a high water content on mild
uremic pruritus; based on this study, the number of
samples needed for a dependent sample was approxi-
mately 50 subjects. Split-body biometrological assess-
ments were performed. The physician investigator
enrolled the subjects into this study, and using a
computer-generated block of four, another investigator
generated the random allocation sequence that divided
the patients into two groups. The identities of the
patients in each group were concealed from both the
investigators and the patients. The on-duty nurses
assigned the participants to the intervention. The partici-
pants, investigators and those assessing the outcomes
were blinded after assignment to the interventions. The
patients in the first group received the sericin cream on
their left extremities (left arm and left leg), while the
other side of the body received the cream base. The
patients in the second group received both the sericin
cream and the cream base, but on opposite sides of
the body from the first group. All of the patients were
shown how to topically apply the assigned treatment
evenly over the area indicated twice daily for a period of
6 weeks after showering.Measurement and outcome
The level of skin hydration on the arms and legs was
assessed using a CorneometerW (KOKO Kosmetikvertrieb
GmbH & Co., Leichlingen, Deutschland). The Cor-
neometerW registers the moisture content in the sur-
face layers of the skin as deep as 10–20 μm; the
presence of capillary blood vessels and superficial
skin fat do not influence this measurement. Skin ir-
ritation or erythema (measured by the redness of the
skin) and skin pigmentation (measured by the mel-
anin content) were assessed using a Mexameter
linked to a Skin Diagnostic SD27 (Courage + Khazaka
electronic GmbH, Köln, Germany). The measurement of
melanin and the erythema readings are based on a light
source with three specific wavelengths; the radiation is
absorbed by the skin and reflected diffusely. A photo-
detector was used to analyze the diffuse reflection from
the skin. The same measuring probe is used to quantify
the skin redness (erythema) and to determine the skin pig-
mentation or the degree of skin darkness (melanin). The
irritating effects of substances and the soothing effects of
active agents can also be recorded by the investigator. Skin
hydration, irritation and pigmentation values have no
units because they are computer- generated based on the
different dielectric constants of water (80.10 at 20°C) and
other substances (typically < 7). The measuring capacitor
shows changes of capacitance according to the moisture
content of the samples (for hydration) and skin color (for
irritation and pigmentation). Each parameter was mea-
sured at least three times in the same randomized area at
patients’ extremities, and the mean value was used for the
analysis. During the study, the patients were advised to
consume similar types and amounts of food and bev-
erages. Activities such as longer exposure to the sunlight
and traveling were to be avoided to reduce any confound-
ing factors. The percent changes in each parameter were
calculated by subtracting the baseline score from the post-
treatment scores at weeks 2, 4 and 6 according to the fol-
lowing equation:
%changes in each parameter ¼ Pt  P0ð Þ=P0½   100;
where P0 is the value of each parameter at baseline (at the
time of enrollment) and Pt is the value of each parameter
during the follow-up period (2, 4 or 6 weeks). All of the
measurements were performed in triplicate.
Because itching is a systemic symptom and likely to be
generalized, most patients could not identify whether
the itching occurred primarily on the right or left side of
the body; therefore, itching was scored as an overall
symptom. The severity of itching was systemically
assessed on both the arms and legs of all patients using
VAS on the enrollment day and every 2 weeks after treat-
ment began. We used a VAS that consisted of a 10-cm
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asked to mark the intensity of their itching on the scale,
with the strongest possible level of itching or unbearable
pruritus marked on the right end of the line (10 cm) and
no itching marked on the left end (0 cm) [50].
Patients’ quality of life
The patients’ quality of life was assessed using the Thai
version of the KDQOL-SF Version 1.3 [51]. Quality of
life was evaluated on the enrollment day and after
6 weeks of treatment. The mean scores for the individual
domain scores and for the three composite summary
scores, which include the mental component score
(MCS), the physical component score (PCS) and the
kidney disease component score (KDCS), were com-
pared as shown in Table 4. For the Hayes algorithm [52],
the raw data obtained from the patients were first trans-
formed into a pre-coded numeric value of 0–100; a
higher transformed score reflected a better quality of life
[51,53].
Safety monitoring
The occurrence of allergic reactions during treatment
with sericin cream was regularly evaluated by two der-
matologists during each visit. The Naranjo algorithm
was used to determine the likelihood of whether an ad-
verse drug reaction was actually caused by the sericin
cream or by other factors.
Statistical analysis
The results are expressed as the mean ± SD unless other-
wise indicated. Statistical analysis was performed using
SPSS version 10.0 (SPSS Inc., Chicago, Illinois, USA). A
bidirectional α-level of significance was set at p= 0.05
for all of the measurements. From the baseline to weeks
2, 4 and 6, the VAS score changes and the levels of skin
hydration, irritation and pigmentation were computed
for each patient within the treatment group using a
repeated measure analysis of variance (ANOVA). The
paired t-test was used to analyze changes in the patients’
quality of life between baseline and 6 weeks after treat-
ment. The differences in each parameter for the patients
receiving the sericin cream and the cream base were
compared at each time point using Student’s t-test.
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